• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

α-取代苯基二氢吡唑啉酮对无鞭毛体的构效关系

Structure Activity Relationship of -Substituted Phenyldihydropyrazolones Against Amastigotes.

作者信息

Sijm Maarten, Maes Louis, de Esch Iwan J P, Caljon Guy, Sterk Geert Jan, Leurs Rob

机构信息

Division of Medicinal Chemistry, Faculty of Sciences, The Amsterdam Institute of Molecular and Life Sciences (AIMMS), Vrije Universiteit Amsterdam, Amsterdam, Netherlands.

Laboratory for Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, Antwerp, Belgium.

出版信息

Front Chem. 2021 Apr 30;9:608438. doi: 10.3389/fchem.2021.608438. eCollection 2021.

DOI:10.3389/fchem.2021.608438
PMID:33996737
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8120161/
Abstract

Current drugs for Chagas disease have long treatment regimens with occurrence of adverse drug effects leading to poor treatment compliance. Novel and efficacious medications are therefore highly needed. We previously reported on the discovery of NPD-0227 (2-isopropyl-5-(4-methoxy-3-(pyridin-3-yl)phenyl)-4,4-dimethyl-2,4-dihydro-3H-pyrazol-3-one) as a potent inhibitor of (pIC = 6.4) with 100-fold selectivity over human MRC-5 cells. The present work describes a SAR study on the exploration of substituents on the phenylpyrazolone nitrogen. Modifications were either done directly onto this pyrazolone nitrogen or alternatively by introducing a piperidine linker. Attention was pointed toward the selection of substituents with a cLogP preferably below NPD-0227s cLogP of 3.5. Generally the more apolar compounds showed better activities then molecules with cLogPs <2.0. Several new compounds were identified with potencies that are in the same range as NPD-0227 (pIC = 6.4) and promising selectivities. While the potency could not be improved, valuable SAR was obtained. Furthermore the introduction of a piperidine linker offers new opportunities for derivatization as valuable novel starting points for future drug discovery.

摘要

目前用于治疗恰加斯病的药物治疗方案冗长,且会出现药物不良反应,导致治疗依从性差。因此,迫切需要新型且有效的药物。我们之前报道了NPD-0227(2-异丙基-5-(4-甲氧基-3-(吡啶-3-基)苯基)-4,4-二甲基-2,4-二氢-3H-吡唑-3-酮)的发现,它是一种有效的 抑制剂(pIC = 6.4),对人MRC-5细胞的选择性是其100倍。本研究描述了对苯基吡唑啉酮氮上取代基进行探索的构效关系(SAR)研究。修饰要么直接在该吡唑啉酮氮上进行,要么通过引入哌啶连接基来实现。重点关注选择cLogP优选低于NPD-0227的3.5的取代基。一般来说,极性较小的化合物比cLogP <2.0的分子表现出更好的活性。鉴定出了几种新化合物,其效力与NPD-0227(pIC = 6.4)处于同一范围,且具有良好的选择性。虽然效力无法提高,但获得了有价值的构效关系。此外,哌啶连接基的引入为衍生化提供了新机会,作为未来药物发现的有价值的新起点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b99/8120161/0fb6363bbc5a/fchem-09-608438-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b99/8120161/c5e81b719ea2/fchem-09-608438-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b99/8120161/d697c7dc4c93/fchem-09-608438-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b99/8120161/f3616aad6edb/fchem-09-608438-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b99/8120161/0fb6363bbc5a/fchem-09-608438-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b99/8120161/c5e81b719ea2/fchem-09-608438-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b99/8120161/d697c7dc4c93/fchem-09-608438-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b99/8120161/f3616aad6edb/fchem-09-608438-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b99/8120161/0fb6363bbc5a/fchem-09-608438-g004.jpg

相似文献

1
Structure Activity Relationship of -Substituted Phenyldihydropyrazolones Against Amastigotes.α-取代苯基二氢吡唑啉酮对无鞭毛体的构效关系
Front Chem. 2021 Apr 30;9:608438. doi: 10.3389/fchem.2021.608438. eCollection 2021.
2
Structure-Activity Relationship of Phenylpyrazolones against Trypanosoma cruzi.苯骈吡唑酮类化合物抗克氏锥虫的构效关系。
ChemMedChem. 2020 Jul 20;15(14):1310-1321. doi: 10.1002/cmdc.202000136. Epub 2020 Apr 27.
3
Identification of Phenylpyrazolone Dimers as a New Class of Anti-Trypanosoma cruzi Agents.鉴定苯骈吡唑酮二聚体为一类新型抗克氏锥虫药物。
ChemMedChem. 2019 Sep 18;14(18):1662-1668. doi: 10.1002/cmdc.201900370. Epub 2019 Aug 23.
4
Complexes of Trypanosoma cruzi sterol 14α-demethylase (CYP51) with two pyridine-based drug candidates for Chagas disease: structural basis for pathogen selectivity.克氏锥虫甾醇 14α-脱甲基酶(CYP51)与两种用于恰加斯病的吡啶类药物候选物的复合物:病原体选择性的结构基础。
J Biol Chem. 2013 Nov 1;288(44):31602-15. doi: 10.1074/jbc.M113.497990. Epub 2013 Sep 18.
5
Efficacy of Novel Pyrazolone Phosphodiesterase Inhibitors in Experimental Mouse Models of Trypanosoma cruzi.新型吡唑啉酮磷酸二酯酶抑制剂在克氏锥虫实验小鼠模型中的疗效
Antimicrob Agents Chemother. 2020 Aug 20;64(9). doi: 10.1128/AAC.00414-20.
6
Efficacy of a series of alpha-pyrone derivatives against Leishmania (L.) infantum and Trypanosoma cruzi.一系列α-吡喃酮衍生物对婴儿利什曼原虫和克氏锥虫的疗效。
Eur J Med Chem. 2017 Oct 20;139:947-960. doi: 10.1016/j.ejmech.2017.08.055. Epub 2017 Sep 1.
7
Structural design, synthesis and pharmacological evaluation of thiazoles against Trypanosoma cruzi.针对克氏锥虫的噻唑类化合物的结构设计、合成及药理学评价
Eur J Med Chem. 2017 Dec 1;141:346-361. doi: 10.1016/j.ejmech.2017.09.047. Epub 2017 Sep 22.
8
Investigating the structure-activity relationships of N'-[(5-nitrofuran-2-yl) methylene] substituted hydrazides against Trypanosoma cruzi to design novel active compounds.研究N'-[(5-硝基呋喃-2-基)亚甲基]取代酰肼对克氏锥虫的构效关系以设计新型活性化合物。
Eur J Med Chem. 2018 Jan 20;144:29-40. doi: 10.1016/j.ejmech.2017.12.011. Epub 2017 Dec 5.
9
Identification of Pyrazolo[3,4-e][1,4]thiazepin based CYP51 inhibitors as potential Chagas disease therapeutic alternative: In vitro and in vivo evaluation, binding mode prediction and SAR exploration.基于吡唑并[3,4-e][1,4]噻氮平的CYP51抑制剂作为恰加斯病潜在治疗选择的鉴定:体外和体内评价、结合模式预测及构效关系探索
Eur J Med Chem. 2018 Apr 10;149:257-268. doi: 10.1016/j.ejmech.2018.02.020. Epub 2018 Feb 23.
10
Evaluation of phthalazinone phosphodiesterase inhibitors with improved activity and selectivity against Trypanosoma cruzi.评估具有改进的对 Trypanosoma cruzi 的活性和选择性的酞嗪酮磷酸二酯酶抑制剂。
J Antimicrob Chemother. 2020 Apr 1;75(4):958-967. doi: 10.1093/jac/dkz516.

引用本文的文献

1
New Amino Naphthoquinone Derivatives as Anti- Agents Targeting Trypanothione Reductase.新型氨基萘醌衍生物作为靶向锥虫硫氧还蛋白还原酶的抗剂
Pharmaceutics. 2022 May 25;14(6):1121. doi: 10.3390/pharmaceutics14061121.

本文引用的文献

1
Structure-Activity Relationship of Phenylpyrazolones against Trypanosoma cruzi.苯骈吡唑酮类化合物抗克氏锥虫的构效关系。
ChemMedChem. 2020 Jul 20;15(14):1310-1321. doi: 10.1002/cmdc.202000136. Epub 2020 Apr 27.
2
Chagas Disease and Heart Failure: An Expanding Issue Worldwide.恰加斯病与心力衰竭:全球范围内日益严重的问题。
Eur Cardiol. 2019 Jul 11;14(2):82-88. doi: 10.15420/ecr.2018.30.2. eCollection 2019 Jul.
3
Chagas Disease: From Discovery to a Worldwide Health Problem.恰加斯病:从发现到全球健康问题
Front Public Health. 2019 Jul 2;7:166. doi: 10.3389/fpubh.2019.00166. eCollection 2019.
4
Access to benznidazole for Chagas disease in the United States-Cautious optimism?在美国,治疗恰加斯病的苯硝唑可及性——谨慎的乐观态度?
PLoS Negl Trop Dis. 2017 Sep 14;11(9):e0005794. doi: 10.1371/journal.pntd.0005794. eCollection 2017 Sep.
5
Predicting a Drug's Membrane Permeability: A Computational Model Validated With in Vitro Permeability Assay Data.预测药物的膜通透性:一个通过体外通透性测定数据验证的计算模型。
J Phys Chem B. 2017 May 25;121(20):5228-5237. doi: 10.1021/acs.jpcb.7b02914. Epub 2017 May 12.
6
Benznidazole for Chronic Chagas' Cardiomyopathy.苯硝唑治疗慢性查加斯心肌病
N Engl J Med. 2016 Jan 14;374(2):189. doi: 10.1056/NEJMc1514453.
7
Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy.随机试验用苯硝唑治疗慢性恰加斯心肌病。
N Engl J Med. 2015 Oct;373(14):1295-306. doi: 10.1056/NEJMoa1507574. Epub 2015 Sep 1.
8
How do antimalarial drugs reach their intracellular targets?抗疟药物是如何作用于其细胞内靶点的?
Front Pharmacol. 2015 May 5;6:91. doi: 10.3389/fphar.2015.00091. eCollection 2015.
9
Fragment-based screening in tandem with phenotypic screening provides novel antiparasitic hits.基于片段的筛选与表型筛选相结合可提供新型抗寄生虫活性物质。
J Biomol Screen. 2015 Jan;20(1):131-40. doi: 10.1177/1087057114549735. Epub 2014 Sep 17.
10
Benznidazole-related adverse drug reactions and their relationship to serum drug concentrations in patients with chronic chagas disease.苯唑哒唑相关药物不良反应及其与慢性恰加斯病患者血清药物浓度的关系。
Antimicrob Agents Chemother. 2013 Jan;57(1):390-5. doi: 10.1128/AAC.01401-12. Epub 2012 Oct 31.